MoonLake Immunotherapeutics (MLTX) Return on Capital Employed (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Return on Capital Employed of 73.0% for Q1 2026, down 3671.0% year-over-year from 2.04% in Q1 2025, and down 11.48% quarter-over-quarter from 65.48% in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Return on Capital Employed (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 73.0% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3671.0% year-over-year to 73.0%; the TTM figure through Mar 2026 stood at 73.0% (down 3671.0% YoY), while the FY2025 annual figure was 60.35%, down 3052.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 73.0%, down from 65.48% in the prior quarter.
- The five-year high for Return on Capital Employed was 131.73% in Q1 2022, with the low at 116.51% in Q3 2022.
- The 5-year median for Return on Capital Employed is 36.28% (2025), against an average of 36.65%.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed jumped 13448 bps in 2022, then sank 22787 bps in 2023.
- MoonLake Immunotherapeutics' Return on Capital Employed stood at 86.69% in 2022, then soared by 88 bps to 10.75% in 2023, then slumped by 180 bps to 30.09% in 2024, then plunged by 118 bps to 65.48% in 2025, then decreased by 11 bps to 73.0% in 2026.
- Business Quant data shows MLTX's Return on Capital Employed at 73.0% in Q1 2026, 65.48% in Q4 2025, and 58.94% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | -60.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -60.74% |
| Mar 31, 2026 | -73.00% |
| Dec 31, 2025 | -65.48% |
| Sep 30, 2025 | -58.94% |
| Jun 30, 2025 | -43.83% |
| Mar 31, 2025 | -36.28% |
| Dec 31, 2024 | -30.09% |
| Sep 30, 2024 | -21.22% |
| Jun 30, 2024 | -14.46% |
| Mar 31, 2024 | -11.37% |
| Dec 31, 2023 | -10.75% |
| Sep 30, 2023 | -11.31% |
| Jun 30, 2023 | -20.60% |
| Mar 31, 2023 | -96.14% |
| Dec 31, 2022 | -86.69% |
| Sep 30, 2022 | -116.51% |
| Jun 30, 2022 | -58.05% |
| Mar 31, 2022 | 131.73% |
| Dec 31, 2021 | -221.17% |